Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138859 | 1.00 | HRH3 (0.37) | HRH3PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20138985 | 1.00 | HRH3 (0.37) | HRH3PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20142921 | 0.84 | PDE4B (0.40) | HRH3PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL25095015 | 0.83 | PDE4B (0.37) | PDE4BPDE4APDE4CPDE4DPDE3A | |
| SCHEMBL20142919 | 0.82 | PDE4B (0.35) | PDE4BPDE4APDE4CPDE4DPDE3A | |
| Cyanide SCHEMBL25408038 | 0.81 | HRH3 (0.33) | HRH3PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20159430 | 0.81 | PDE4B (0.38) | HRH3PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20159108 | 0.81 | PDE4B (0.38) | PDE4BPDE4APDE4CPDE4DPDE3A | |
| SCHEMBL20159102 | 0.79 | PDE4B (0.39) | HRH3PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20159121 | 0.79 | PDE4B (0.39) | HRH3PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612372-B2 | Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20230278963-A1 | NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-07 | — | — | US | disclosed |
| EP-4169909-A1 | NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021256900-A1 | NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | 한국과학기술연구원 | 2021-12-23 | — | — | WO | disclosed |
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612372-B2 | Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof | MAPT, MAP2, MAP1B | HRH3 2492/4885PDE4B 3924/4885PDE4A 3419/4885 |
| US-20230278963-A1 | NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | DPP4, QDPR, DPYD | HRH3 2323/4885PDE4B 1642/4885PDE4A 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.